BOPA and Compassly article in New Scientist

Compassly featured in New Scientist: Shining a Light on Digital Innovation in Cancer Pharmacy Training

We are excited to share that Compassly has been featured in the prestigious New Scientist magazine, alongside the British Oncology Pharmacy Association (BOPA), for our work in transforming digital competencies and professional training.

With the increasing complexity of oncology care, the need for streamlined and adaptable training methods has never been more critical. Partnering with organisations like BOPA helps us empower cancer care professionals every day, ensuring they have the confidence and expertise to deliver the best patient outcomes.

Supporting Training for Oncology Pharmacy Professionals

The feature highlights the unique challenges faced by those in oncology pharmacy, where every decision and action can impact patient safety and well-being, particularly in the evolving landscape of novel cancer therapies. The BOPA digital SACT Verification passport on Compassly has been designed to meet these challenges head-on, allowing pharmacy teams to continuously assess their competencies, identify areas for improvement, and ensure that training is up-to-date and in line with the latest standards and protocols.

The passport provides healthcare teams with tools to track, assess, and develop the skills required for safe, effective cancer treatment in a dynamic healthcare landscape.

Looking into the Future

Being featured in the New Scientist alongside BOPA is an exciting milestone for us at Compassly. As we continue to innovate and evolve, our focus remains on supporting healthcare professionals by providing them with the tools they need to succeed in their roles.

Our collaboration with BOPA and the oncology pharmacy community is a key step in ensuring that healthcare professionals are equipped with the skills, knowledge, and confidence to deliver exceptional care, now and in the future.

To read the full article, visit New Scientist.